Collplant Biotechnologies Valuation
| CLGN Stock | USD 4.25 0.00 0.00% |
At this time, the firm appears to be undervalued. Collplant Biotechnologies shows a prevailing Real Value of $7.25 per share. The current price of the firm is $4.25. Our model approximates the value of Collplant Biotechnologies from analyzing the firm fundamentals such as Shares Outstanding of 11.45 M, operating margin of (17.69) %, and Return On Equity of -0.62 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Collplant Biotechnologies' valuation include:
Price Book 2.3527 | Enterprise Value 33.2 M | Enterprise Value Ebitda (5.97) | Price Sales 70.9049 | Forward PE 15.5521 |
Undervalued
Today
Please note that Collplant Biotechnologies' price fluctuation is slightly risky at this time. Calculation of the real value of Collplant Biotechnologies is based on 3 months time horizon. Increasing Collplant Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Collplant Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Collplant Stock. However, Collplant Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.25 | Real 7.25 | Target 16.92 | Hype 4.39 | Naive 4.02 |
The intrinsic value of Collplant Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Collplant Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Collplant Biotechnologies helps investors to forecast how Collplant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Collplant Biotechnologies more accurately as focusing exclusively on Collplant Biotechnologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Collplant Biotechnologies' intrinsic value based on its ongoing forecasts of Collplant Biotechnologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Collplant Biotechnologies' closest peers.
Collplant Biotechnologies Cash |
|
Collplant Valuation Trend
Knowing Collplant Biotechnologies' actual value is paramount for traders when making sound investment determinations. Using both Collplant Biotechnologies' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Collplant Biotechnologies Total Value Analysis
Collplant Biotechnologies is currently forecasted to have valuation of 33.23 M with market capitalization of 48.85 M, debt of 3.16 M, and cash on hands of 36.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Collplant Biotechnologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
33.23 M | 48.85 M | 3.16 M | 36.29 M |
Collplant Biotechnologies Investor Information
The book value of the company was currently reported as 1.81. The company recorded a loss per share of 1.53. Collplant Biotechnologies last dividend was issued on the 21st of November 2016. The entity had 2:3 split on the 21st of November 2016. Based on the key indicators related to Collplant Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Collplant Biotechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Collplant Biotechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Collplant Biotechnologies has an asset utilization ratio of 32.11 percent. This suggests that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Collplant Biotechnologies is more efficient with each dollar of assets it utilizes for everyday operations.Collplant Biotechnologies Ownership Allocation
The market capitalization of Collplant Biotechnologies is $48.85 Million. Collplant Biotechnologies shows 10.1 percent of its outstanding shares held by insiders and 12.23 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Collplant Biotechnologies Profitability Analysis
The company reported the previous year's revenue of 10.96 M. Net Loss for the year was (7.02 M) with profit before overhead, payroll, taxes, and interest of 13.64 M.About Collplant Biotechnologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Collplant Biotechnologies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Collplant Biotechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Collplant Biotechnologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Collplant Biotechnologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Collplant Biotechnologies. We calculate exposure to Collplant Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Collplant Biotechnologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9 M | 9.4 M | |
| Pretax Profit Margin | (0.64) | (0.67) | |
| Operating Profit Margin | (0.69) | (0.72) | |
| Net Loss | (0.64) | (0.67) | |
| Gross Profit Margin | 0.82 | 0.86 |
Collplant Biotechnologies Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 11.4 M | |
| Forward Price Earnings | 15.5521 |
Collplant Biotechnologies Current Valuation Indicators
Collplant Biotechnologies' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Collplant Biotechnologies' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Collplant Biotechnologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Collplant Biotechnologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Collplant Biotechnologies' worth.When determining whether Collplant Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Collplant Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Collplant Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Collplant Biotechnologies Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.